Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 4
2015 8
2016 13
2017 12
2018 8
2019 10
2020 11
2021 7
2022 3
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, Bozovic A, Danser AHJ, Geurts F, Hoorn EJ, Touw DJ, Larsen EL, Poulsen HE, Kramer MHH, Nieuwdorp M, Joles JA, van Raalte DH. van Bommel EJM, et al. Among authors: muskiet mha. Kidney Int. 2020 Jan;97(1):202-212. doi: 10.1016/j.kint.2019.09.013. Epub 2019 Oct 10. Kidney Int. 2020. PMID: 31791665 Free article. Clinical Trial.
Understanding EMPA-REG OUTCOME.
Muskiet MH, van Raalte DH, van Bommel EJ, Smits MM, Tonneijck L. Muskiet MH, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):928-9. doi: 10.1016/S2213-8587(15)00424-6. Lancet Diabetes Endocrinol. 2015. PMID: 26590679 No abstract available.
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH. van Bommel EJM, et al. Among authors: muskiet mha. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. doi: 10.2215/CJN.06080616. Epub 2017 Mar 2. Clin J Am Soc Nephrol. 2017. PMID: 28254770 Free PMC article. Review.
SGLT2 inhibitors: expanding their Empire beyond diabetes.
Muskiet MHA, Heerspink HJL, van Raalte DH. Muskiet MHA, et al. Lancet Diabetes Endocrinol. 2021 Feb;9(2):59-61. doi: 10.1016/S2213-8587(20)30428-9. Epub 2020 Dec 22. Lancet Diabetes Endocrinol. 2021. PMID: 33357504 No abstract available.
Diabetes care in older people: a call for action.
Muskiet MHA, Elders PJM, van Raalte DH. Muskiet MHA, et al. Lancet Healthy Longev. 2023 Dec;4(12):e657-e659. doi: 10.1016/S2666-7568(23)00234-9. Lancet Healthy Longev. 2023. PMID: 38042157 Free article. No abstract available.
67 results